Business Description
Aldeyra Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US01438T1060
Total Employee Number:
7Description
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.19 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.37 | |||||
Debt-to-EBITDA | -0.62 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 19.9 | |||||
3-Year EPS without NRI Growth Rate | 19.2 | |||||
3-Year FCF Growth Rate | 17 | |||||
3-Year Book Growth Rate | -34.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 61.14 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.85 | |||||
9-Day RSI | 66.64 | |||||
14-Day RSI | 63.24 | |||||
3-1 Month Momentum % | -4.33 | |||||
6-1 Month Momentum % | -66.37 | |||||
12-1 Month Momentum % | -55.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.72 | |||||
Quick Ratio | 2.72 | |||||
Cash Ratio | 2.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -53.76 | |||||
ROA % | -34.69 | |||||
ROIC % | -127.39 | |||||
3-Year ROIIC % | 131.63 | |||||
ROC (Joel Greenblatt) % | -7502.65 | |||||
ROCE % | -47.17 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 172.73 | |||||
PB Ratio | 2.93 | |||||
Price-to-Tangible-Book | 2.94 | |||||
EV-to-EBIT | -2.91 | |||||
EV-to-EBITDA | -2.94 | |||||
EV-to-Forward-Revenue | 14.83 | |||||
EV-to-FCF | -2.85 | |||||
| Price-to-Net-Current-Asset-Value | 2.94 | |||||
| Price-to-Net-Cash | 3.08 | |||||
Earnings Yield (Greenblatt) % | -34.36 | |||||
FCF Yield % | -21.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aldeyra Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.387 | ||
| Beta | 4.5337 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.1 | ||
| Volatility % | 105.96 | ||
| 14-Day RSI | 63.24 | ||
| 14-Day ATR (€) | 0.093178 | ||
| 20-Day SMA (€) | 1.5695 | ||
| 12-1 Month Momentum % | -55.32 | ||
| 52-Week Range (€) | 1.0505 - 5.052 | ||
| Shares Outstanding (Mil) | 60.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aldeyra Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aldeyra Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 37 days | ||
| General meeting for 2026 | 2026-06-09 09:00 | 1.50 (+3.45%) | ||
| Guidance call for 2026 | 2026-06-04 08:45 | 1.58 (+13.67%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.47 (+0.68%) | ||
| Annual report for 2025 | 2026-02-27 | 4.62 (-1.74%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 10:40 | 4.38 (+4.69%) | ||
| Jefferies Global Healthcare Conference | 2025-11-20 11:30 | 4.22 (+0.96%) | ||
| Guidance call for 2025 | 2025-11-13 08:00 | 4.55 (+2.02%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 4.29 (-3.47%) |
Show
Entries
Aldeyra Therapeutics Inc Frequently Asked Questions
What is Aldeyra Therapeutics Inc(FRA:137)'s stock price today?
The current price of FRA:137 is €1.82. The 52 week high of FRA:137 is €5.05 and 52 week low is €1.05.
When is next earnings date of Aldeyra Therapeutics Inc(FRA:137)?
The next earnings date of Aldeyra Therapeutics Inc(FRA:137) is 2026-08-07 Est..
Does Aldeyra Therapeutics Inc(FRA:137) pay dividends? If so, how much?
Aldeyra Therapeutics Inc(FRA:137) does not pay dividend.
Press Release
Articles on Aldeyra Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers